President Barack Obama raised $738.5 million for his successful re-election effort, almost as much as the record $745 million he brought in four years earlier, Federal Election Commission filings show.
Drugmakers may push to boost U.S. government spending on prescription drugs even as the U.S. Congress seeks to reduce health-care spending, according to internal documents from the industry’s top lobbying group.
The U.S. risks losing thousands of research jobs as countries led by Singapore, Ireland and South Africa boost incentives to woo drugmakers, said John Castellani, head of a pharmaceutical industry lobbying group.
MF Global Holdings Ltd. argued in a December 2010 letter to regulators that futures brokers didn’t need tighter restrictions on how they invest client funds. Ten months later, as MF Global filed for bankruptcy, about $1.6 billion in customer accounts was missing.
President Barack Obama’s budget plan would trim spending on federal health programs at the expense of drugmakers, hospitals and nursing homes while seeking nearly $1 billion for carrying out the 2010 health-care law.
When House Republicans took power in 1995 determined to cut spending in a battle that shut down the U.S. government, then-House Speaker Newt Gingrich was persuaded to spare the National Institutes of Health.
Pfizer Inc. and Merck & Co. are being pulled into an expanding congressional investigation about the agreement drugmakers reached with the Obama administration to support the Democrats’ overhaul of the U.S. health-care system, according to three people familiar with the talks.